{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:58:15Z","timestamp":1786982295171,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:00:00Z","timestamp":1495756800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s12185-017-2264-7","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T04:40:08Z","timestamp":1495773608000},"page":"3-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan"],"prefix":"10.1007","volume":"106","author":[{"name":"For TTP group of Blood Coagulation Abnormalities Research Team, Research on Rare and Intractable Disease supported by Health, Labour, and Welfare Sciences Research Grants","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kokame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Higasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Moriki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,26]]},"reference":[{"key":"2264_CR1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1146\/annurev.med.53.082901.103948","volume":"53","author":"JL Moake","year":"2002","unstructured":"Moake JL. Thrombotic thrombocytopenic purpura: the systemic clumping \u201cplague\u201d. Annu Rev Med. 2002;53:75\u201388.","journal-title":"Annu Rev Med"},{"key":"2264_CR2","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","volume":"339","author":"M Furlan","year":"1998","unstructured":"Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578\u201384.","journal-title":"N Engl J Med"},{"key":"2264_CR3","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","volume":"339","author":"HM Tsai","year":"1998","unstructured":"Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585\u201394.","journal-title":"N Engl J Med"},{"key":"2264_CR4","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:1847\u20138.","journal-title":"N Engl J Med"},{"key":"2264_CR5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","volume":"413","author":"GG Levy","year":"2001","unstructured":"Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488\u201394.","journal-title":"Nature"},{"key":"2264_CR6","doi-asserted-by":"crossref","first-page":"11902","DOI":"10.1073\/pnas.172277399","volume":"99","author":"K Kokame","year":"2002","unstructured":"Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA. 2002;99:11902\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2264_CR7","doi-asserted-by":"crossref","first-page":"41059","DOI":"10.1074\/jbc.C100515200","volume":"276","author":"X Zheng","year":"2001","unstructured":"Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059\u201363.","journal-title":"J Biol Chem"},{"key":"2264_CR8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s002770050184","volume":"72","author":"Furlan M Von","year":"1996","unstructured":"Von Furlan M. Willebrand factor: molecular size and functional activity. Ann Hematol. 1996;72:341\u20138.","journal-title":"Ann Hematol"},{"key":"2264_CR9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0092-8674(00)80983-6","volume":"84","author":"B Savage","year":"1996","unstructured":"Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996;84:289\u201397.","journal-title":"Cell"},{"key":"2264_CR10","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","volume":"87","author":"M Furlan","year":"1996","unstructured":"Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223\u201334.","journal-title":"Blood"},{"key":"2264_CR11","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","volume":"87","author":"HM Tsai","year":"1996","unstructured":"Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87:4235\u201344.","journal-title":"Blood"},{"key":"2264_CR12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2003-08-2861","volume":"103","author":"K Kokame","year":"2004","unstructured":"Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood. 2004;103:607\u201312.","journal-title":"Blood"},{"key":"2264_CR13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","volume":"129","author":"K Kokame","year":"2005","unstructured":"Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129:93\u2013100.","journal-title":"Br J Haematol"},{"key":"2264_CR14","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1537-2995.2006.00914.x","volume":"46","author":"S Kato","year":"2006","unstructured":"Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006;46:1444\u201352.","journal-title":"Transfusion"},{"key":"2264_CR15","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood-2003-05-1616","volume":"102","author":"F Scheiflinger","year":"2003","unstructured":"Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003;102:3241\u20133.","journal-title":"Blood"},{"key":"2264_CR16","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","volume":"109","author":"S Ferrari","year":"2007","unstructured":"Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood. 2007;109:2815\u201322.","journal-title":"Blood"},{"key":"2264_CR17","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1055\/s-0038-1651380","volume":"34","author":"CK Kasper","year":"1975","unstructured":"Kasper CK, Pool JG. Letter: measurement of mild factor VIII inhibitors in Bethesda units. Thromb Diath Haemorrh. 1975;34:875\u20136.","journal-title":"Thromb Diath Haemorrh"},{"key":"2264_CR18","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","volume":"115","author":"JA Kremer Hovinga","year":"2010","unstructured":"Kremer Hovinga JA, Vesely SK, Terrell DR, L\u00e4mmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500\u201311.","journal-title":"Blood"},{"key":"2264_CR19","doi-asserted-by":"crossref","first-page":"e33029","DOI":"10.1371\/journal.pone.0033029","volume":"7","author":"M Matsumoto","year":"2012","unstructured":"Matsumoto M, Bennett CL, Isonishi A, Qureshi Z, Hori Y, Hayakawa M, et al. Acquired Idiopathic ADAMTS13 Activity Deficient Thrombotic Thrombocytopenic Purpura in a Population from Japan. PLoS One. 2012;7:e33029.","journal-title":"PLoS One"},{"key":"2264_CR20","first-page":"21","volume":"24","author":"E Moschcowitz","year":"1924","unstructured":"Moschcowitz E. Hyaline Thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc. 1924;24:21\u20134.","journal-title":"Proc N Y Pathol Soc"},{"key":"2264_CR21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-196603000-00003","volume":"45","author":"EL Amorosi","year":"1966","unstructured":"Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45:139\u201359.","journal-title":"Medicine"},{"key":"2264_CR22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393\u20137.","journal-title":"N Engl J Med"},{"key":"2264_CR23","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.V2.6.542.542","volume":"2","author":"K Singer","year":"1947","unstructured":"Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura; hemorrhagic diathesis with generalized platelet thromboses. Blood. 1947;2:542\u201354.","journal-title":"Blood"},{"key":"2264_CR24","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","volume":"307","author":"JL Moake","year":"1982","unstructured":"Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432\u20135.","journal-title":"N Engl J Med"},{"key":"2264_CR25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0049-3848(85)90180-X","volume":"38","author":"Y Asada","year":"1985","unstructured":"Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res. 1985;38:469\u201379.","journal-title":"Thromb Res"},{"key":"2264_CR26","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V98.6.1765","volume":"98","author":"A Veyradier","year":"2001","unstructured":"Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001;98:1765\u201372.","journal-title":"Blood"},{"key":"2264_CR27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","volume":"102","author":"SK Vesely","year":"2003","unstructured":"Vesely SK, George JN, L\u00e4mmle B, Studt JD, Alberio L, El-Harake MA, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60\u20138.","journal-title":"Blood"},{"key":"2264_CR28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.seminhematol.2003.10.009","volume":"41","author":"M Matsumoto","year":"2004","unstructured":"Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol. 2004;41:68\u201374.","journal-title":"Semin Hematol"},{"key":"2264_CR29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15:312\u201322.","journal-title":"J Thromb Haemost"},{"key":"2264_CR30","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1538-7836.2005.01436.x","volume":"3","author":"DR Terrell","year":"2005","unstructured":"Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3:1432\u20136.","journal-title":"J Thromb Haemost"},{"key":"2264_CR31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","volume":"142","author":"M Scully","year":"2008","unstructured":"Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142:819\u201326.","journal-title":"Br J Haematol"},{"key":"2264_CR32","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","volume":"103","author":"XL Zheng","year":"2004","unstructured":"Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043\u20139.","journal-title":"Blood"},{"key":"2264_CR33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.md.0000133622.03370.07","volume":"83","author":"P Coppo","year":"2004","unstructured":"Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004;83:233\u201344.","journal-title":"Medicine (Baltimore)"},{"key":"2264_CR34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","volume":"158","author":"M Scully","year":"2012","unstructured":"Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323\u201335.","journal-title":"Br J Haematol"},{"key":"2264_CR35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1751-553X.2011.01380.x","volume":"34","author":"G Zini","year":"2012","unstructured":"Zini G, d\u2019Onofrio G, Briggs C, Erber W, Jou JM, Lee SH, et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Lab Hematol. 2012;34:107\u201316.","journal-title":"Int J Lab Hematol"},{"key":"2264_CR36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10157-016-1276-6","volume":"20","author":"H Kato","year":"2016","unstructured":"Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, et al. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016;20:536\u201343.","journal-title":"Clin Exp Nephrol"},{"key":"2264_CR37","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/0002-9378(93)90043-I","volume":"169","author":"BM Sibai","year":"1993","unstructured":"Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 1993;169:1000\u20136.","journal-title":"Am J Obstet Gynecol"},{"key":"2264_CR38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF01696619","volume":"70","author":"A Pereira","year":"1995","unstructured":"Pereira A, Mazzara R, Monteagudo J, Sanz C, Puig L, Martinez A, et al. Thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol. 1995;70:319\u201323.","journal-title":"Ann Hematol"},{"key":"2264_CR39","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","volume":"89","author":"CL Balduini","year":"2010","unstructured":"Balduini CL, Gugliotta L, Luppi M, Laurenti L, Klersy C, Pieresca C, et al. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol. 2010;89:591\u20136.","journal-title":"Ann Hematol"},{"key":"2264_CR40","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMoa1406617","volume":"371","author":"LB Holst","year":"2014","unstructured":"Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371:1381\u201391.","journal-title":"N Engl J Med"},{"key":"2264_CR41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199902113400601","volume":"340","author":"PC Hebert","year":"1999","unstructured":"Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340:409\u201317.","journal-title":"N Engl J Med"},{"key":"2264_CR42","doi-asserted-by":"crossref","first-page":"E127","DOI":"10.1002\/ajh.23997","volume":"90","author":"Y Benhamou","year":"2015","unstructured":"Benhamou Y, Baudel JL, Wynckel A, Galicier L, Azoulay E, Provot F, et al. Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center. Am J Hematol. 2015;90:E127\u20139.","journal-title":"Am J Hematol"},{"key":"2264_CR43","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/trf.12943","volume":"55","author":"A Kumar","year":"2015","unstructured":"Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AA, Kleinman S, et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion. 2015;55:1116\u201327.","journal-title":"Transfusion"},{"key":"2264_CR44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12185-016-2019-x","volume":"104","author":"Y Miyakawa","year":"2016","unstructured":"Miyakawa Y, Imada K, Ichinohe T, Nishio K, Abe T, Murata M, et al. Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy. Int J Hematol. 2016;104:228\u201335.","journal-title":"Int J Hematol"},{"key":"2264_CR45","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1111\/trf.13182","volume":"55","author":"A Isonishi","year":"2015","unstructured":"Isonishi A, Bennett CL, Plaimauer B, Scheiflinger F, Matsumoto M, Fujimura Y. Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma. Transfusion. 2015;55:2321\u201330.","journal-title":"Transfusion"},{"key":"2264_CR46","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","volume":"118","author":"M Scully","year":"2011","unstructured":"Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746\u201353.","journal-title":"Blood"},{"key":"2264_CR47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","volume":"40","author":"A Froissart","year":"2012","unstructured":"Froissart A, Buffet M, Veyradier A, Poullin P, Prov\u00f4t F, Malot S, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40:104\u201311.","journal-title":"Crit Care Med"},{"key":"2264_CR48","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","volume":"52","author":"F Beloncle","year":"2012","unstructured":"Beloncle F, Buffet M, Coindre JP, Munoz-Bongrand N, Malot S, Pene F, et al. Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion. 2012;52:2436\u201344.","journal-title":"Transfusion"},{"key":"2264_CR49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1537-2995.2005.03146.x","volume":"45","author":"A Ziman","year":"2005","unstructured":"Ziman A, Mitri M, Klapper E, Pepkowitz SH, Goldfinger D. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution\u2019s experience and review of the literature. Transfusion. 2005;45:41\u20139.","journal-title":"Transfusion"},{"key":"2264_CR50","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ajh.21385","volume":"84","author":"A Nosari","year":"2009","unstructured":"Nosari A, Redaelli R, Caimi TM, Mostarda G, Morra E. Cyclosporine therapy in refractory\/relapsed patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2009;84:313\u20134.","journal-title":"Am J Hematol"},{"key":"2264_CR51","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","volume":"130","author":"MC Kappers-Klunne","year":"2005","unstructured":"Kappers-Klunne MC, Wijermans P, Fijnheer R, Croockewit AJ, van der Holt B, de Wolf JT, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2005;130:768\u201376.","journal-title":"Br J Haematol"},{"key":"2264_CR52","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2169\/internalmedicine.52.8253","volume":"52","author":"N Kawano","year":"2013","unstructured":"Kawano N, Yokota-Ikeda N, Yoshida S, Kuriyama T, Yamashita K, Sugio Y, et al. Therapeutic modality of 11 patients with TTP in a single institution in Miyazaki from 2000 to 2011. Intern Med. 2013;52:1883\u201391.","journal-title":"Intern Med"},{"key":"2264_CR53","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","volume":"93","author":"F Peyvandi","year":"2008","unstructured":"Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93:232\u20139.","journal-title":"Haematologica"},{"key":"2264_CR54","first-page":"79","volume":"22","author":"JV Dacie","year":"1953","unstructured":"Dacie JV, Mollison PL, Richardson N, Selwyn JG, Shapiro L. Atypical congenital haemolytic anaemia. Q J Med. 1953;22:79\u201398.","journal-title":"Q J Med"},{"key":"2264_CR55","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood.V16.1.943.943","volume":"16","author":"I Schulman","year":"1960","unstructured":"Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood. 1960;16:943\u201357.","journal-title":"Blood"},{"key":"2264_CR56","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM197806152982407","volume":"298","author":"JD Upshaw Jr","year":"1978","unstructured":"Upshaw JD Jr. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med. 1978;298:1350\u20132.","journal-title":"N Engl J Med"},{"key":"2264_CR57","first-page":"368","volume":"300","author":"S Rennard","year":"1979","unstructured":"Rennard S, Abe S. Decreased cold-insoluble globulin in congenital thrombocytopenia (Upshaw-Schulman syndrome). N Engl J Med. 1979;300:368.","journal-title":"N Engl J Med"},{"key":"2264_CR58","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V89.9.3097","volume":"89","author":"M Furlan","year":"1997","unstructured":"Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097\u2013103.","journal-title":"Blood"},{"key":"2264_CR59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF02982558","volume":"74","author":"S Kinoshita","year":"2001","unstructured":"Kinoshita S, Yoshioka A, Park YD, Shizashi H, Konno M, Funato M, et al. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol. 2001;74:101\u20138.","journal-title":"Int J Hematol"},{"key":"2264_CR60","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/asheducation-2015.1.631","volume":"2015","author":"JE Sadler","year":"2015","unstructured":"Sadler JE. What\u2019s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Progr. 2015;2015:631\u20136.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"2264_CR61","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5482\/HAMO-13-04-0026","volume":"33","author":"M Mansouri Taleghani","year":"2013","unstructured":"Mansouri Taleghani M, von Krogh AS, Fujimura Y, George JN, Hrachovinova I, Knobl PN, et al. Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie. 2013;33:138\u201343.","journal-title":"Hamostaseologie"},{"key":"2264_CR62","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1538-7836.2011.04399.x","volume":"9","author":"K Kokame","year":"2011","unstructured":"Kokame K, Kokubo Y, Miyata T. Polymorphisms and mutations of ADAMTS13 in the Japanese population and estimation of the number of patients with Upshaw-Schulman syndrome. J Thromb Haemost. 2011;9:1654\u20136.","journal-title":"J Thromb Haemost"},{"key":"2264_CR63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-3-319-08717-7_5","volume-title":"ADAMTS13","author":"Y Fujimura","year":"2015","unstructured":"Fujimura Y, Kokame K, Yagi H, Isonishi A, Matsumoto M, Miyata T. Hereditary deficiency of ADAMTS13 activity: Upshaw-Schulman syndrome. In: Rodgers MD, editor. ADAMTS13. Switzerland: Springer; 2015. p. 73\u201390."},{"key":"2264_CR64","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2141.2008.07515.x","volume":"144","author":"Y Fujimura","year":"2009","unstructured":"Fujimura Y, Matsumoto M, Kokame K, Isonishi A, Soejima K, Akiyama N, et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol. 2009;144:742\u201354.","journal-title":"Br J Haematol"},{"key":"2264_CR65","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1160\/TH11-11-0799","volume":"107","author":"F Taguchi","year":"2012","unstructured":"Taguchi F, Yagi H, Matsumoto M, Sadamura S, Isonishi A, Soejima K, et al. The homozygous p. C1024R- ADAMTS13 gene mutation links to a late-onset phenotype of Upshaw-Schulman syndrome in Japan. Thromb Haemost. 2012;107:1003\u20135.","journal-title":"Thromb Haemost"},{"key":"2264_CR66","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood-2003-06-1796","volume":"103","author":"M Matsumoto","year":"2004","unstructured":"Matsumoto M, Kokame K, Soejima K, Miura M, Hayashi S, Fujii Y, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood. 2004;103:1305\u201310.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2264_CR67","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","volume":"9","author":"Y Fujimura","year":"2011","unstructured":"Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011;9(Suppl 1):283\u2013301.","journal-title":"J Thromb Haemost"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2264-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2264-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2264-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T15:15:54Z","timestamp":1692803754000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2264-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,26]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["2264"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2264-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,26]]}}}